Gland Pharma · NSE: GLAND · BSE: 543245
Q2 FY23 results · Jul–Sep 2022
Gland Pharma reported revenue from operations of ₹1,044.40 crore (down 3.3% from Q2 FY22) and net profit of ₹241.24 crore (down 20.1% from Q2 FY22) for Q2 FY23 (Jul–Sep 2022), on a consolidated basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,044.40 | 1,080.47 | −3.3% | 856.90 | +21.9% |
| Other income | 65.62 | 51.20 | +28.2% | 74.39 | −11.8% |
| Total income | 1,110.03 | 1,131.67 | −1.9% | 931.29 | +19.2% |
| Profit before tax | 324.08 | 400.67 | −19.1% | 308.50 | +5.1% |
| Net profit for the period | 241.24 | 302.08 | −20.1% | 229.17 | +5.3% |
| EPS, basic (₹) | 14.65 | 18.37 | −20.3% | 13.93 | +5.2% |
| Net margin (%) | 23.1 | 28.0 | 26.7 |
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,048.31 | 1,080.47 | −3.0% | 856.90 | +22.3% |
| Other income | 65.62 | 51.20 | +28.2% | 74.39 | −11.8% |
| Total income | 1,113.93 | 1,131.67 | −1.6% | 931.29 | +19.6% |
| Profit before tax | 322.47 | 400.70 | −19.5% | 308.78 | +4.4% |
| Net profit for the period | 239.63 | 302.12 | −20.7% | 229.45 | +4.4% |
| EPS, basic (₹) | 14.55 | 18.37 | −20.8% | 13.95 | +4.3% |
| Net margin (%) | 22.9 | 28.0 | 26.8 |
Consolidated
- Filed with BSE
- 27 Oct 2022, 10:08 IST
- Board meeting
- 26 Oct 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 Oct 2022, 10:08 IST
- Board meeting
- 26 Oct 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE